|Chemical and physical data|
|Molar mass||429.406 g·mol−1|
|3D model (JSmol)|
GNF6702 is the name for a broad-spectrum antiprotozoal drug invented by researchers working at the Genomics Institute of the Novartis Research Foundation in 2013, with activity against leishmaniasis, Chagas disease and sleeping sickness. These three diseases are caused by related kinetoplastid parasites, which share similar biology. GNF6702 acts as allosteric proteasome inhibitor which was effective against infection with any of the three protozoal diseases in mice, while having little evident toxicity to mammalian cells.
- Biggart A, et al. Compounds and compositions for the treatment of parasitic diseases. US20150175613, priority date Dec 19, 2013
- Khare S, et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature 2016 doi:10.1038/nature19339
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|